The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This is a single center, open-label, nonrandomized, Phase 1b, dose-escalation study designed to determine maximum tolerated dose (MTD) of CKD-516 in combination with durvalumab and evaluate the safety and tolerability profile, efficacy of CKD-516 and durvalumab treatment.
创建时间：
2021-02-15
